# Shake and bake: a robust and cost-effective proteomic sample preparation workflow for plasma and cerebrospinal fluid

**Authors:** John Rönnholm, Sophia Weiner, Johannes Fuchs, Annika Thorsell, Carina Sihlbom, Laura Dugom, Amy Easton, Henrik Zetterberg, Johan Gobom

PMC · DOI: 10.1186/s12014-026-09589-1 · Clinical Proteomics · 2026-02-15

## TL;DR

This paper introduces a cost-effective and scalable method for preparing plasma and cerebrospinal fluid samples to improve the detection of low-abundance proteins for biomarker discovery in neurodegenerative diseases.

## Contribution

A new sample preparation workflow that combines high-abundance protein depletion and optimized digestion for improved proteome coverage in plasma and CSF.

## Key findings

- Depletion of high-abundance proteins increased identified proteins by ~65% in CSF and ~80% in plasma.
- A two-step digestion protocol using Lys-C/trypsin followed by trypsin improved reproducibility and detectability in plasma.
- The workflow showed high reproducibility in a 528-sample ALS cohort with intra-sample CVs lower than inter-individual variation.

## Abstract

Plasma and cerebrospinal fluid are complementary sources of biomarkers for neurodegenerative diseases. The wide dynamic range of protein abundances, particularly in plasma, hampers detection of low-abundance proteins. Depletion of high-abundance proteins and efficient enzymatic digestion can improve proteome coverage but must be carefully optimized for reproducibility, throughput, and cost-efficiency for use in large-scale clinical proteomic studies.

We developed a scalable sample preparation workflow for plasma and cerebrospinal fluid (CSF) that integrates depletion of high-abundance proteins, optimized digestion using Lys-C and trypsin, and compatibility with both label-free and tandem mass tag (TMTpro)-based quantification. Depletion was performed using a multi-affinity resin with immobilized antibodies targeting 14 high-abundance plasma proteins, which collectively constitute ≈ 95% of total plasma protein content. We systematically evaluated protein depletion and enzyme digestion conditions, and the effect of deoxycholate on digestion, monitoring the number of detectable proteins and the quantitation precision.

A resin-to-plasma ratio of ≥ 75 and a mixing speed of 900 rpm ensured complete and reproducible depletion. Depletion resulted in an increase in the number of identified proteins by ~ 65% in CSF, and ~ 80% in plasma, tripling the number of brain-enriched proteins, with maintained quantitative precision (median coefficient of variation (CV) for relative protein abundances < 11%). A two-step digestion protocol using Lys-C/trypsin followed by trypsin yielded the highest reproducibility and detectability in plasma. Adding the detergent deoxycholate to the samples had little effect in CSF and only marginally improved proteome coverage for plasma but decreased quantification precision and throughput. Technical replicates from a 528-sample clinical amyotrophic lateral sclerosis (ALS) cohort showed high reproducibility, with intra-sample CVs substantially lower than inter-individual variation.

The sample preparation workflow described here enabled deep and reproducible proteome profiling of plasma and CSF in high-throughput formats and was found to be suitable for biomarker discovery in large clinical studies.

The online version contains supplementary material available at 10.1186/s12014-026-09589-1.

## Linked entities

- **Chemicals:** deoxycholate (PubChem CID 222528)
- **Diseases:** amyotrophic lateral sclerosis (MONDO:0004976)

## Full-text entities

- **Genes:** CNTN1 (contactin 1) [NCBI Gene 1272] {aka CMYO12, CMYP12, F3, GP135, MYPCN}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}, TBC1D30 (TBC1 domain family member 30) [NCBI Gene 23329], MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, PTPA (protein phosphatase 2 phosphatase activator) [NCBI Gene 5524] {aka PARK25, PP2A, PPP2R4, PR53}, SERPINA1 (serpin family A member 1) [NCBI Gene 5265] {aka A1A, A1AT, AAT, PI, PI1, PRO2275}, APLP1 (amyloid beta precursor like protein 1) [NCBI Gene 333] {aka APLP}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, ZG16B (zymogen granule protein 16B) [NCBI Gene 124220] {aka EECP, HRPE773, JCLN2, PAUF, PRO1567}, CNDP1 (carnosine dipeptidase 1) [NCBI Gene 84735] {aka CN1, CPGL2, HsT2308}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, QDPR (quinoid dihydropteridine reductase) [NCBI Gene 5860] {aka DHPR, HDHPR, PKU2, SDR33C1}, LCN1 (lipocalin 1) [NCBI Gene 3933] {aka PMFA, TLC, TP, VEGP}, B4GALT1 (beta-1,4-galactosyltransferase 1) [NCBI Gene 2683] {aka B4GAL-T1, CDG2D, CLDLFIB, GGTB2, GT1, GTB}, FITM1 (fat storage inducing transmembrane protein 1) [NCBI Gene 161247] {aka FIT1}, PTPRZ1 (protein tyrosine phosphatase receptor type Z1) [NCBI Gene 5803] {aka HPTPZ, HPTPzeta, PTP-ZETA, PTP18, PTPRZ, PTPZ}, AKAP9 (A-kinase anchoring protein 9) [NCBI Gene 10142] {aka AKAP-9, AKAP350, AKAP450, CG-NAP, HYPERION, LQT11}, EEF1E1 (eukaryotic translation elongation factor 1 epsilon 1) [NCBI Gene 9521] {aka AIMP3, P18}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, TIGD7 (tigger transposable element derived 7) [NCBI Gene 91151] {aka Sancho}, BPIFB1 (BPI fold containing family B member 1) [NCBI Gene 92747] {aka C20orf114, LPLUNC1}, S100A7 (S100 calcium binding protein A7) [NCBI Gene 6278] {aka PSOR1, S100A7c}, NRCAM (neuronal cell adhesion molecule) [NCBI Gene 4897] {aka NEDNMS}, NTM (neurotrimin) [NCBI Gene 50863] {aka CEPU-1, HNT, IGLON2, NTRI}, USP1 (ubiquitin specific peptidase 1) [NCBI Gene 7398] {aka UBP}, A2M (alpha-2-macroglobulin) [NCBI Gene 2] {aka A2MD, CPAMD5, FWP007, S863-7}, PHOX2B (paired like homeobox 2B) [NCBI Gene 8929] {aka CCHS, NBLST2, NBPhox, PMX2B}, LRRTM2 (leucine rich repeat transmembrane neuronal 2) [NCBI Gene 26045], ANXA1 (annexin A1) [NCBI Gene 301] {aka ANX1, LPC1}, GMFB (glia maturation factor beta) [NCBI Gene 2764] {aka GMF}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, NSF (N-ethylmaleimide sensitive factor, vesicle fusing ATPase) [NCBI Gene 4905] {aka DEE96, SEC18, SKD2}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}, KARS1 (lysyl-tRNA synthetase 1) [NCBI Gene 3735] {aka CMTRIB, DEAPLE, DFNB89, KARS, KARS2, KRS}, HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, CLDN5 (claudin 5) [NCBI Gene 7122] {aka AWAL, BEC1, CPETRL1, TMDVCF, TMVCF}
- **Diseases:** amyotrophic lateral sclerosis (MESH:D000690), HCD (MESH:D004213), FAIMS (MESH:D014086), Dementia (MESH:D003704), neurodegenerative disease (MESH:D019636), Huntington's disease (MESH:D006816), AD (MESH:D000544), CNS diseases (MESH:D002493), neuroinflammation (MESH:D000090862)
- **Chemicals:** Phosphate-buffered saline (-), disulfide (MESH:D004220), hydroxylamine (MESH:D019811), trichloroacetic acid (MESH:D014238), TFA (MESH:D014269), DIA (MESH:C076868), BCA (MESH:C047117), TEAB (MESH:C041737), cysteine (MESH:D003545), perchloric acid (MESH:C576518), Lys (MESH:D008239), proline (MESH:D011392), methanol (MESH:D000432), DOC (MESH:D003840), Tris(2)-carboxyethylphosphine (MESH:C080938), FA (MESH:C030544), ACN (MESH:C032159), water (MESH:D014867), IAA (MESH:D007460), Peptides (MESH:D010455), HCl (MESH:D006851), B (MESH:D001895)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12927225/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12927225/full.md

---
Source: https://tomesphere.com/paper/PMC12927225